Status:
NO_LONGER_AVAILABLE
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo....
Eligibility Criteria
Inclusion
- Subject who complete the A1481244 study and require Sildenafil (Revatio TM) 20 mg TID therapy.
- All women of childbearing potential must use adequate contraception throughout the study and four weeks after completion of the study
Exclusion
- Pregnant or lactating women
- Participation in other studies during study participation
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00878943
Last Update
February 1 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
The Institute of Medical Sciences, CARE Hospital
Hyderabad, Andhra Pradesh, India, 500 001
2
Mehta Hospital & Cardiopulmonary Care Center
Ahmedabad, Gujarat, India, 380 054
3
Bankers Heart Institute
Vadodara, Gujarat, India, 390 015
4
St Johns Medical College Hospital
Bangalore, Karnataka, India, 560 034